EMERYVILLE, Calif., Nov. 1, 2016 /PRNewswire/ -- Berkeley Lights, Inc. (BLI), a company dedicated to the development of transformational technologies for biopharmaceutical processes announced today a two-year strategic collaboration agreement with F. Hoffman-LaRoche, Ltd. and Hoffman-LaRoche Inc. (Roche). The collaboration focuses on the innovation and automation of Roche's antibody discovery technology using BLI's platforms. As part of the collaboration, Roche and Berkeley Lights will leverage BLI's opto-nanofluidic systems and devices to increase efficiency, selection, and speed with which novel therapeutics are discovered.
"Our mission is to provide platforms that transform cell based biological processes to speed the discovery, development, and delivery of therapeutics to market to help advance care for patients," said Igor Khandros, PhD, BLI co-founder and chief executive officer. "Roche is a recognized leader in the pharmaceutical industry and we are excited to have been selected as their collaboration partner." About Berkeley Lights: ¿Berkeley Lights, Inc. (BLI) develops and commercializes platforms on which many bio-pharmaceutical, genomic, and cellular therapy applications will run. BLI is launching its first commercial platform the Beacon™ in December 2016. The Beacon will initially be released for single cell based antibody discovery and cell line development with additional capabilities being added in 2017, including gene editing and T-Cell therapy research. Expanding on the foundation of its technology, BLI will continue development on cell and gene therapy platforms. BLI's transformative platforms will enable a capability leap in single cell-by-cell differentiation, measurement and culture to ultimately empower the reactivation of a patient's own immune system to defeat diseases such as cancer as well as autoimmune disorders.